(PharmaNewsWire.Com, November 04, 2021 ) According to a new market research report "Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes (Insulin, Glucagon-Like Peptide-1), Growth Hormone Therapy, Osteoporosis, Fertility), End User (Homecare and Hospitals), and Region - Global Forecast to 2022", published by MarketsandMarkets™, the global Injection Pen Market is expected to reach USD 41.38 Billion by 2022 from USD 30.97 Billion in 2017, at a CAGR of 6.0% during the forecast period (2017-2022). The key factors driving the growth of this market include rising prevalence of chronic diseases, favorable reimbursement scenario and government support, and the increasing number of regulatory approvals resulting in the increased adoption amongst patients.
Disposable injection pens accounted for the largest share of the market in 2017
The Injection Pen Market is segmented on the basis of type into disposable and reusable injection pens. In 2017, the disposable injection pens segment accounted for the largest share of the global market due to the benefits disposable injection pens offer such as portability, ease of use, and low possibility of infection.
By therapy, the diabetes segment accounted for the largest share of the market in 2017
On the basis of therapy, the Injection Pen Market is segmented into diabetes, growth hormone therapy, osteoporosis, fertility, and other therapies. In 2017, the diabetes segment accounted for the largest share of the global market. The large share of this segment can be primarily attributed to large diabetic population across the globe, new drug therapies for the treatment of diabetes, and a favorable reimbursement scenario in developed countries.
The home care segment dominated the market on the basis of end users in 2017
The Injection Pen Market is segmented on the basis of end users into home care and hospital & clinics. In 2017, homecare segment accounted for the largest share of the global market. Majority of injection pens are used for self-administration of drugs, and are rarely recommended for hospital use to avoid the risk of infection due to use on multiple patients. Factors such as the growing prevalence of chronic diseases and technological advancements are driving the growth of this segment.
North America held the largest share of the market in 2017
In 2017, North America accounted for the largest share of the Injection Pen Market, followed by Europe. Factors such as increasing geriatric population in Canada, increasing FDA approvals, and rising prevalence of chronic diseases in the US and Canada are contributing to the large share of this geographical segment.
The key players in the global Injection Pen Market are Novo Nordisk (Denmark), Eli Lilly (US), Sanofi (France), Ypsomed (Switzerland), Merck (Germany), AstraZeneca (UK), F. Hoffman-la Roche (Switzerland), Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Pfizer (US), and Haselmeier (Switzerland).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
